Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients
about
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in TanzaniaPharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysisAnti-tuberculosis drug induced hepatotoxicity among TB/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control studyInvolvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control studyCharacterizing plasma albumin concentration changes in TB/HIV patients on anti retroviral and anti -tuberculosis therapy.Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureClinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populationsPharmacogenomics of antimicrobial agents.CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.PharmGKB summary: Efavirenz pathway, pharmacokineticsHepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.Correlation of CpG Island Methylation of the Cytochrome P450 2E1/2D6 Genes with Liver Injury Induced by Anti-Tuberculosis Drugs: A Nested Case-Control Study.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.An Update on Drug-induced Liver Injury.HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians.Latest advances in predicting DILI in human subjects: focus on biomarkers.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.The pharmacological challenges of treating tuberculosis and HIV coinfections.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts.Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study.Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population.
P2860
Q27011622-89B7895C-BB99-4591-B0ED-3B512A500014Q28481272-B12AF45A-98FB-44A9-BD34-2FA0208C8312Q28484468-098C6341-F450-4D52-943D-6F1EC2806336Q28488142-DAE26A42-43F7-45B8-A0FB-61C6F49C568CQ28544822-7DDAD5E6-EDCA-4F20-A245-11134EB37EBEQ34235116-8AD33F22-C564-477B-A25C-08609FB8CD20Q34298935-6B0FAF75-7B93-4D00-84D1-B7D7EB9C700EQ34444338-5500A006-3BBA-4DAC-8914-20116713E926Q34778035-955106AB-349F-41F9-9A82-1BC8B7B65B46Q34826590-4A6F27DA-41B6-42FE-8DC3-937E8911E2D9Q34977413-17146372-A9E6-4BBF-B628-5E40ED68F7F4Q35039268-955E1111-5FA7-4A29-9C20-3370940CA710Q35142786-655CB0CA-A170-4329-B63A-1474360D201CQ35547723-E76FAE11-8959-468F-A2C9-A6A5C5386CA9Q35706069-45E384A6-1796-43E7-A7BF-479249AA3B7CQ36058879-07CE5CA4-AB7C-493D-80A3-193B74CC1D79Q36145491-313579AF-EDB7-4525-A0FB-40ADB35A9CFDQ37202900-A7F36E20-A439-427B-81DB-5848E8A936AEQ37613267-C57F6FFC-8BD2-4373-9A08-E24D13C8F50DQ37613520-F9E0EA56-728E-4877-8436-FD91C464FA6FQ37667333-C2D3A035-071F-40D3-B4DE-8E0146B4D887Q38045377-693ED3F2-73BB-479C-9506-3DA640D6C52DQ38360770-1D6E610F-A996-4AEE-8A1E-0C58797FD65DQ38733565-A426020D-39FA-48FF-AD8B-DC76260125D7Q38855121-92DF98F7-52DD-4944-8A33-D1C259C4ED6FQ38861140-418A92B1-DEEB-486C-B24B-139ABB85601EQ39003762-4627DC33-BDED-4DF6-AB5B-6D446FA2C00FQ39039468-81E5E2D7-CC9D-4E55-8111-B855C770F31EQ39158128-3FADE10B-14B8-4A04-BD8A-FD2C3A9505F6Q40563423-F6FD1820-0DB2-4BB3-8028-BD619DCC4C55Q42263059-302308E3-40C2-43BC-B1FC-FA4CEE1D8C57Q42696007-C7B95C4D-BDB6-4DDE-9084-BC0DCB86E079Q42872165-C5DD7CB9-1C51-451E-AB47-B59D9EAAE208Q43474583-D9B51D85-F021-469C-BBC2-187BDA131EE1Q44132038-9CF4838B-C40B-4624-9222-883C1111B9C1Q47766129-48C50924-C55A-4517-BB7D-472021D9C74FQ51569750-7DE2DC28-F46B-48E8-9CFF-B9A8C0293995Q52330065-154ECEE5-D1EB-4C85-B78D-CA557BA3A11BQ52707803-D1590A49-AD24-4EBB-8362-276878B888A2Q53734594-B41E33F1-4CEC-4081-8BD1-55E92154D7D5
P2860
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@ast
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@en
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@nl
type
label
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@ast
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@en
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@nl
prefLabel
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@ast
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@en
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@nl
P2093
P2860
P50
P3181
P1433
P1476
Pharmacogenetic & pharmacokine ...... ry in TB-HIV infected patients
@en
P2093
Abiy Habtewold
Akira Suda
Getachew Aderaye
Klaus-Dieter Riedel
Lars Lindquist
Nobuhisa Ueda
Wondwossen Amogne
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0027810
P407
P577
2011-01-01T00:00:00Z